The online home of Neurology Reviews

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Just over half of MS patients get DMD therapy

Publish date:: March 1, 2019

Key clinical point: DMD treatment in this commercial population was low.

Major finding: Among MS patients followed for 2 years, 43% had no claim for a DMD.

Study details: A retrospective administrative claims study of 63,946 patients with MS.

Disclosures: Funding for the study was provided by EMD Serono, a Merck company. Dr. Phillips is an employee of the company.

Citation:

Phillips A et al. ACTRIMS FORUM 2019, Abstract 001.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,